Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AMDL has said that its subsidiary in China, Jade Pharmaceuticals, has set up production and applied for China State Food and Drug Administration approval to market the cancer drug docetaxel.
Subscribe to our email newsletter
AMDL said its subsidiary’s sales network is uniquely positioned to take advantage of the significant marketing opportunity in China. Docetaxel is an anticancer drug that interferes with the growth of cancer cells.
“There is an enormous need in China for effective and affordable cancer drugs, with more than 1.6 million new cases of the disease annually,” said Gary Dreher, AMDL CEO.
“Docetaxel is extremely useful because it can treat a broad spectrum of cancers, including breast cancer, non-small cell lung cancer, stomach cancer and prostate cancer.”
According to AMDL, docetaxel currently generates more than $2 billion in sales globally. This drug currently represents approximately $200 million in sales in China.